25 XP   0   0   10

Anixa Biosciences Inc
Buy, Hold or Sell?

Let's analyse Anixa together

PenkeI guess you are interested in Anixa Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Anixa Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Anixa Biosciences Inc

I send you an email if I find something interesting about Anixa Biosciences Inc.

Quick analysis of Anixa (30 sec.)










What can you expect buying and holding a share of Anixa? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$0.74
Expected worth in 1 year
$0.64
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$-0.10
Return On Investment
-3.5%

For what price can you sell your share?

Current Price per Share
$2.98
Expected price per share
$2.75 - $3.8
How sure are you?
50%

1. Valuation of Anixa (5 min.)




Live pricePrice per Share (EOD)

$2.98

Intrinsic Value Per Share

$-3.14 - $-1.75

Total Value Per Share

$-2.40 - $-1.01

2. Growth of Anixa (5 min.)




Is Anixa growing?

Current yearPrevious yearGrowGrow %
How rich?$23.6m$29.3m-$4.9m-20.5%

How much money is Anixa making?

Current yearPrevious yearGrowGrow %
Making money-$2.6m-$2.9m$317.2k12.1%
Net Profit Margin-673.4%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Anixa (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#560 / 1010

Most Revenue
#634 / 1010

Most Profit
#338 / 1010

Most Efficient
#768 / 1010

What can you expect buying and holding a share of Anixa? (5 min.)

Welcome investor! Anixa's management wants to use your money to grow the business. In return you get a share of Anixa.

What can you expect buying and holding a share of Anixa?

First you should know what it really means to hold a share of Anixa. And how you can make/lose money.

Speculation

The Price per Share of Anixa is $2.98. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Anixa.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Anixa, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.74. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Anixa.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-3.4%-0.08-2.8%-0.09-3.2%-0.09-3.0%-0.07-2.5%
Usd Book Value Change Per Share0.010.2%-0.03-0.9%-0.05-1.7%0.031.0%0.020.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.2%-0.03-0.9%-0.05-1.7%0.031.0%0.020.8%
Usd Price Per Share4.54-3.84-4.26-3.82-3.27-
Price to Earnings Ratio-11.12--11.53--11.55--11.21--8.88-
Price-to-Total Gains Ratio621.57-80.50--118.40-4.61--114.44-
Price to Book Ratio6.14-5.03-4.68-9.62-18.10-
Price-to-Total Gains Ratio621.57-80.50--118.40-4.61--114.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.98
Number of shares335
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.03
Usd Total Gains Per Share-0.030.03
Gains per Quarter (335 shares)-8.689.69
Gains per Year (335 shares)-34.7438.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-35-4503929
20-69-8007868
30-104-1150116107
40-139-1500155146
50-174-1850194185
60-208-2200233224
70-243-2550271263
80-278-2900310302
90-313-3250349341
100-347-3600388380

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.037.00.07.5%5.0132.00.03.6%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%7.013.00.035.0%15.025.00.037.5%47.082.08.034.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%7.00.0130.05.1%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%7.013.00.035.0%15.025.00.037.5%48.082.07.035.0%

Fundamentals of Anixa

About Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Fundamental data was last updated by Penke on 2024-04-11 00:39:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Anixa Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Anixa earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Anixa to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Anixa Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-673.4%+673.4%
TTM-673.4%YOY0.0%-673.3%
TTM-673.4%5Y-82.9%-590.5%
5Y-82.9%10Y-344.6%+261.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM-673.4%-216.8%-456.6%
YOY0.0%-282.3%+282.3%
5Y-82.9%-436.8%+353.9%
10Y-344.6%-597.3%+252.7%
1.1.2. Return on Assets

Shows how efficient Anixa is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Anixa to the Biotechnology industry mean.
  • -12.8% Return on Assets means that Anixa generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Anixa Biosciences Inc:

  • The MRQ is -12.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.8%TTM-10.0%-2.8%
TTM-10.0%YOY-9.4%-0.6%
TTM-10.0%5Y-18.4%+8.3%
5Y-18.4%10Y-21.9%+3.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.8%-13.3%+0.5%
TTM-10.0%-12.8%+2.8%
YOY-9.4%-11.6%+2.2%
5Y-18.4%-13.8%-4.6%
10Y-21.9%-15.6%-6.3%
1.1.3. Return on Equity

Shows how efficient Anixa is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Anixa to the Biotechnology industry mean.
  • -13.2% Return on Equity means Anixa generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Anixa Biosciences Inc:

  • The MRQ is -13.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.2%TTM-10.4%-2.8%
TTM-10.4%YOY-9.7%-0.7%
TTM-10.4%5Y-20.3%+9.9%
5Y-20.3%10Y-22.2%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-16.9%+3.7%
TTM-10.4%-16.1%+5.7%
YOY-9.7%-14.9%+5.2%
5Y-20.3%-19.3%-1.0%
10Y-22.2%-20.1%-2.1%

1.2. Operating Efficiency of Anixa Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Anixa is operating .

  • Measures how much profit Anixa makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Anixa to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Anixa Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-793.7%+793.7%
TTM-793.7%YOY0.0%-793.7%
TTM-793.7%5Y-112.8%-680.9%
5Y-112.8%10Y-337.8%+225.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-793.7%-238.5%-555.2%
YOY0.0%-288.4%+288.4%
5Y-112.8%-486.2%+373.4%
10Y-337.8%-628.4%+290.6%
1.2.2. Operating Ratio

Measures how efficient Anixa is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Anixa Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8.206-8.206
TTM8.206YOY0.000+8.206
TTM8.2065Y1.096+7.110
5Y1.09610Y3.568-2.472
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM8.2063.310+4.896
YOY0.0003.838-3.838
5Y1.0965.679-4.583
10Y3.5687.823-4.255

1.3. Liquidity of Anixa Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Anixa is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 15.19 means the company has $15.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Anixa Biosciences Inc:

  • The MRQ is 15.192. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.936. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ15.192TTM14.936+0.256
TTM14.936YOY21.760-6.824
TTM14.9365Y15.049-0.112
5Y15.04910Y10.229+4.820
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.1923.863+11.329
TTM14.9364.169+10.767
YOY21.7605.337+16.423
5Y15.0496.122+8.927
10Y10.2296.434+3.795
1.3.2. Quick Ratio

Measures if Anixa is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Anixa to the Biotechnology industry mean.
  • A Quick Ratio of 28.31 means the company can pay off $28.31 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Anixa Biosciences Inc:

  • The MRQ is 28.307. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 27.268. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ28.307TTM27.268+1.038
TTM27.268YOY29.434-2.166
TTM27.2685Y20.864+6.404
5Y20.86410Y14.043+6.821
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.3073.504+24.803
TTM27.2683.991+23.277
YOY29.4345.371+24.063
5Y20.8646.088+14.776
10Y14.0436.395+7.648

1.4. Solvency of Anixa Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Anixa assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Anixa to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07 means that Anixa assets are financed with 7.0% credit (debt) and the remaining percentage (100% - 7.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Anixa Biosciences Inc:

  • The MRQ is 0.070. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.073. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.070TTM0.073-0.003
TTM0.073YOY0.054+0.019
TTM0.0735Y0.103-0.031
5Y0.10310Y0.330-0.227
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0700.339-0.269
TTM0.0730.337-0.264
YOY0.0540.271-0.217
5Y0.1030.368-0.265
10Y0.3300.388-0.058
1.4.2. Debt to Equity Ratio

Measures if Anixa is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Anixa to the Biotechnology industry mean.
  • A Debt to Equity ratio of 7.2% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Anixa Biosciences Inc:

  • The MRQ is 0.072. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.075. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.072TTM0.075-0.003
TTM0.075YOY0.055+0.020
TTM0.0755Y0.114-0.039
5Y0.11410Y2.703-2.589
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0720.392-0.320
TTM0.0750.403-0.328
YOY0.0550.335-0.280
5Y0.1140.427-0.313
10Y2.7030.461+2.242

2. Market Valuation of Anixa Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Anixa generates.

  • Above 15 is considered overpriced but always compare Anixa to the Biotechnology industry mean.
  • A PE ratio of -11.12 means the investor is paying $-11.12 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Anixa Biosciences Inc:

  • The EOD is -7.301. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.123. Based on the earnings, the company is expensive. -2
  • The TTM is -11.529. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.301MRQ-11.123+3.822
MRQ-11.123TTM-11.529+0.405
TTM-11.529YOY-11.552+0.023
TTM-11.5295Y-11.209-0.320
5Y-11.20910Y-8.884-2.325
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.301-2.300-5.001
MRQ-11.123-2.656-8.467
TTM-11.529-2.718-8.811
YOY-11.552-4.145-7.407
5Y-11.209-6.258-4.951
10Y-8.884-6.315-2.569
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Anixa Biosciences Inc:

  • The EOD is -10.292. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.680. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.153. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.292MRQ-15.680+5.388
MRQ-15.680TTM-22.153+6.472
TTM-22.153YOY-19.628-2.525
TTM-22.1535Y-23.150+0.997
5Y-23.15010Y-24.280+1.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.292-2.974-7.318
MRQ-15.680-3.306-12.374
TTM-22.153-3.508-18.645
YOY-19.628-5.613-14.015
5Y-23.150-8.378-14.772
10Y-24.280-8.873-15.407
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Anixa is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.14 means the investor is paying $6.14 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Anixa Biosciences Inc:

  • The EOD is 4.027. Based on the equity, the company is fair priced.
  • The MRQ is 6.136. Based on the equity, the company is overpriced. -1
  • The TTM is 5.032. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.027MRQ6.136-2.108
MRQ6.136TTM5.032+1.103
TTM5.032YOY4.684+0.348
TTM5.0325Y9.616-4.583
5Y9.61610Y18.102-8.487
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0271.914+2.113
MRQ6.1362.116+4.020
TTM5.0322.097+2.935
YOY4.6842.881+1.803
5Y9.6163.550+6.066
10Y18.1023.936+14.166
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Anixa Biosciences Inc.

3.1. Institutions holding Anixa Biosciences Inc

Institutions are holding 13.957% of the shares of Anixa Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc4.36650.00011392906299842.2
2023-12-31UBS Group AG1.820.0007580578-23861-3.9476
2023-12-31Mission Wealth Management, LLC1.57110.063150116800
2023-12-31Laird Norton Tyee Trust Co1.15620.16923688353688350
2023-12-31Geode Capital Management, LLC0.97950.0001312472128264.2804
2023-12-31Long Focus Capital Management, LLC0.51940.021416570100
2023-12-31BlackRock Inc0.49150156797-4769-2.9517
2023-12-31State Street Corporation0.3401010850064006.2684
2023-12-31Bank of New York Mellon Corp0.3030.000196654570.059
2023-12-31Susquehanna International Group, LLP0.22980.0001733033664599.9645
2023-12-31Raymond James & Associates0.17440.000255649-933-1.6489
2023-12-31Northern Trust Corp0.1614051497-1947-3.6431
2023-12-31Qube Research & Technologies0.15190.000448453484491211225
2023-12-31JANE STREET GROUP, LLC0.136043383433830
2023-09-30Citadel Advisors Llc0.1272040575-2117-4.9588
2023-12-31CAMBRIDGE Invest RESEARCH ADVISORS, INC.0.12540.000740000-100-0.2494
2023-12-31CI Private Wealth LLC0.11720.0003374001740087
2023-12-31Morgan Stanley - Brokerage Accounts0.1143036473-388-1.0526
2023-12-31Gemmer Asset Management LLC0.10970.01673500000
2023-12-31LPL Financial Corp0.08820.00012814240.0142
Total 13.08280.27324173486+529868+12.7%

3.2. Funds holding Anixa Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.90860.000292784100
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.31870.001442065800
2024-02-29Fidelity Extended Market Index0.53990.0016172230-834-0.4819
2023-09-30BlackRock Extended Mkt Composite0.26220.00198364600
2024-03-31BlackRock Extended Equity Market K0.22880.001673000260.0356
2024-03-28iShares Micro-Cap ETF0.20680.02246595700
2024-02-29Fidelity Total Market Index0.16380.00025225700
2024-02-29Fidelity Series Total Market Index0.12880.00024109900
2023-12-31NT Ext Equity Mkt Idx Fd - L0.08230.00172625000
2023-12-31Northern Trust Extended Eq Market Idx0.08230.00172625000
2024-02-29Fidelity Nasdaq Composite Index0.07560.00052410200
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0730.00142327800
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.06610.000321079-906762-97.7282
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.06610.00022107900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05860.001418696350.1876
2024-02-29Spartan Total Market Index Pool E0.0520.00021658400
2024-02-29Spartan Extended Market Index Pool E0.04280.001913650541965.8365
2024-02-29Schwab Total Stock Market Index0.04010.00021278500
2024-02-29Vanguard Balanced Index Inv0.03950.00011259900
2024-02-29Vanguard U.S. Eq Idx £ Acc0.03360.00021072900
Total 6.46960.03932063769-902116-43.7%

3.3. Insider Transactions

Insiders are holding 4.855% of the shares of Anixa Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-15Amit KumarBUY300003.22
2024-03-15Arnold M BaskiesBUY100003.63
2023-07-31Amit KumarSELL118003.57
2023-07-20Michael CatelaniBUY55003.64

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Anixa Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.007-0.026+455%-0.050+779%0.029-75%0.023-68%
Book Value Per Share--0.7400.764-3%0.920-20%0.645+15%0.382+93%
Current Ratio--15.19214.936+2%21.760-30%15.049+1%10.229+49%
Debt To Asset Ratio--0.0700.073-4%0.054+29%0.103-32%0.330-79%
Debt To Equity Ratio--0.0720.075-5%0.055+30%0.114-37%2.703-97%
Dividend Per Share----0%-0%-0%0.000-100%
Eps---0.102-0.084-17%-0.095-7%-0.088-13%-0.074-27%
Free Cash Flow Per Share---0.072-0.051-29%-0.057-21%-0.047-36%-0.033-54%
Free Cash Flow To Equity Per Share---0.001-0.031+2022%-0.054+3611%0.077-102%0.042-103%
Gross Profit Margin--1.0041.001+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---1.751--------
Intrinsic Value_10Y_min---3.138--------
Intrinsic Value_1Y_max---0.140--------
Intrinsic Value_1Y_min---0.218--------
Intrinsic Value_3Y_max---0.447--------
Intrinsic Value_3Y_min---0.742--------
Intrinsic Value_5Y_max---0.787--------
Intrinsic Value_5Y_min---1.358--------
Market Cap95061404.000-52%144825092.000122574981.500+18%135733649.000+7%121841286.100+19%104420725.571+39%
Net Profit Margin----6.7340%0.0000%-0.8290%-3.4460%
Operating Margin----7.9370%0.0000%-1.1280%-3.3780%
Operating Ratio---8.206-100%0.000-100%1.096-100%3.568-100%
Pb Ratio4.027-52%6.1365.032+22%4.684+31%9.616-36%18.102-66%
Pe Ratio-7.301+34%-11.123-11.529+4%-11.552+4%-11.209+1%-8.884-20%
Price Per Share2.980-52%4.5403.843+18%4.255+7%3.820+19%3.273+39%
Price To Free Cash Flow Ratio-10.292+34%-15.680-22.153+41%-19.628+25%-23.150+48%-24.280+55%
Price To Total Gains Ratio407.989-52%621.56780.504+672%-118.404+119%4.607+13391%-114.437+118%
Quick Ratio--28.30727.268+4%29.434-4%20.864+36%14.043+102%
Return On Assets---0.128-0.100-22%-0.094-26%-0.184+43%-0.219+71%
Return On Equity---0.132-0.104-21%-0.097-27%-0.203+53%-0.222+68%
Total Gains Per Share--0.007-0.026+455%-0.050+779%0.029-75%0.023-69%
Usd Book Value--23604000.00024368250.000-3%29356250.000-20%20574907.850+15%12201619.825+93%
Usd Book Value Change Per Share--0.007-0.026+455%-0.050+779%0.029-75%0.023-68%
Usd Book Value Per Share--0.7400.764-3%0.920-20%0.645+15%0.382+93%
Usd Dividend Per Share----0%-0%-0%0.000-100%
Usd Eps---0.102-0.084-17%-0.095-7%-0.088-13%-0.074-27%
Usd Free Cash Flow---2309000.000-1632500.000-29%-1820750.000-21%-1485494.950-36%-1063922.600-54%
Usd Free Cash Flow Per Share---0.072-0.051-29%-0.057-21%-0.047-36%-0.033-54%
Usd Free Cash Flow To Equity Per Share---0.001-0.031+2022%-0.054+3611%0.077-102%0.042-103%
Usd Market Cap95061404.000-52%144825092.000122574981.500+18%135733649.000+7%121841286.100+19%104420725.571+39%
Usd Price Per Share2.980-52%4.5403.843+18%4.255+7%3.820+19%3.273+39%
Usd Profit---3255000.000-2622750.000-19%-2940000.000-10%-2790898.400-14%-2302304.550-29%
Usd Revenue---91500.000-100%617250000.000-100%123667907.950-100%61922883.550-100%
Usd Total Gains Per Share--0.007-0.026+455%-0.050+779%0.029-75%0.023-69%
 EOD+2 -6MRQTTM+16 -16YOY+12 -205Y+16 -1610Y+17 -17

4.2. Fundamental Score

Let's check the fundamental score of Anixa Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.301
Price to Book Ratio (EOD)Between0-14.027
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than128.307
Current Ratio (MRQ)Greater than115.192
Debt to Asset Ratio (MRQ)Less than10.070
Debt to Equity Ratio (MRQ)Less than10.072
Return on Equity (MRQ)Greater than0.15-0.132
Return on Assets (MRQ)Greater than0.05-0.128
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Anixa Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.170
Ma 20Greater thanMa 503.157
Ma 50Greater thanMa 1003.383
Ma 100Greater thanMa 2003.800
OpenGreater thanClose3.250
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-01-31. Currency in USD. All numbers in thousands.

Summary
Total Assets25,372
Total Liabilities1,768
Total Stockholder Equity24,605
 As reported
Total Liabilities 1,768
Total Stockholder Equity+ 24,605
Total Assets = 25,372

Assets

Total Assets25,372
Total Current Assets25,219
Long-term Assets153
Total Current Assets
Cash And Cash Equivalents 998
Short-term Investments 22,800
Net Receivables 391
Other Current Assets 1,030
Total Current Assets  (as reported)25,219
Total Current Assets  (calculated)25,219
+/-0
Long-term Assets
Property Plant Equipment 153
Long-term Assets Other 0
Long-term Assets  (as reported)153
Long-term Assets  (calculated)153
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,660
Long-term Liabilities108
Total Stockholder Equity24,605
Total Current Liabilities
Short-term Debt 54
Accounts payable 364
Other Current Liabilities 1,242
Total Current Liabilities  (as reported)1,660
Total Current Liabilities  (calculated)1,660
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt108
Long-term Liabilities  (as reported)108
Long-term Liabilities  (calculated)108
+/-0
Total Stockholder Equity
Common Stock318
Retained Earnings -231,451
Other Stockholders Equity 255,738
Total Stockholder Equity (as reported)24,605
Total Stockholder Equity (calculated)24,605
+/-0
Other
Capital Stock318
Cash and Short Term Investments 23,798
Common Stock Shares Outstanding 31,446
Liabilities and Stockholders Equity 25,372
Net Debt -836
Net Invested Capital 24,605
Net Working Capital 23,559
Property Plant and Equipment Gross 153
Short Long Term Debt Total 162



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-01-312023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-12-012017-10-312017-07-312017-04-302017-01-312016-10-312016-07-312016-04-302016-01-312015-10-312015-07-312015-04-302015-01-312014-10-312014-07-312014-04-302014-01-312013-10-312013-07-312013-04-302013-01-312012-10-312012-07-312012-04-302012-01-312011-10-312011-07-312011-04-302011-01-312010-10-312010-07-312010-04-302010-01-312009-10-312009-07-312009-04-302009-01-312008-10-312008-07-312008-04-302008-01-312007-10-312007-07-312007-04-302007-01-312006-10-312006-07-312006-04-302006-01-312005-10-312005-07-312005-04-302005-01-312004-10-312004-07-312004-04-302004-01-312003-10-312003-07-312003-04-302003-01-312002-10-312002-07-312002-04-302002-01-312001-10-312001-07-312001-04-302001-01-312000-10-312000-07-312000-04-302000-01-311999-10-311999-07-311999-04-301999-01-311998-10-311998-07-311998-04-301998-01-311997-10-311997-07-311997-04-301997-01-311996-10-311996-07-311996-04-301996-01-311995-10-311995-07-311995-04-301995-01-311994-10-311994-07-311994-04-301994-01-311993-10-311993-07-311993-04-301993-01-311992-10-311992-07-311992-04-301992-01-311991-10-311991-07-311991-04-301991-01-311990-10-311990-07-311990-04-301990-01-311989-10-311989-07-311989-04-301989-01-311988-10-311988-07-311988-04-301988-01-311987-10-311987-07-311987-04-301987-01-311986-10-311986-07-311986-04-301986-01-311985-10-31
> Total Assets 
3,300
0
0
0
1,500
0
0
0
1,200
0
0
0
2,100
0
0
0
4,200
4,200
4,200
4,200
4,200
4,300
4,200
4,200
4,300
4,500
4,500
4,300
4,400
5,700
6,000
7,900
8,700
7,700
7,200
7,400
6,600
6,000
7,200
9,400
9,700
11,500
15,400
23,400
24,700
23,100
22,500
21,400
20,000
18,300
16,300
15,000
13,300
12,700
11,700
10,500
8,100
8,100
9,740
9,302
6,895
6,302
5,771
7,542
6,562
8,737
7,381
3,575
2,732
2,732
1,826
2,331
2,330
2,131
2,516
2,281
2,316
2,347
2,068
1,756
1,466
1,646
1,696
1,601
1,864
2,048
1,977
1,820
1,870
24,283
21,204
14,624
7,498
6,054
6,008
8,077
9,848
9,711
10,175
8,625
10,046
10,046
8,627
10,169
8,646
8,029
6,794
5,887
5,661
7,522
7,354
5,308
5,440
10,327
10,500
13,399
9,055
13,270
11,133
10,279
9,336
8,647
7,206
6,321
5,628
4,219
7,249
8,415
8,812
8,812,416
7,491
7,361
7,294
6,449
6,470
7,765
6,843
6,294
6,164
5,925
9,362
9,453
14,604
38,498
37,062
36,257
35,238
32,797
32,563
30,412
28,306
27,599
26,578
25,522
25,372
25,37225,52226,57827,59928,30630,41232,56332,79735,23836,25737,06238,49814,6049,4539,3625,9256,1646,2946,8437,7656,4706,4497,2947,3617,4918,812,4168,8128,4157,2494,2195,6286,3217,2068,6479,33610,27911,13313,2709,05513,39910,50010,3275,4405,3087,3547,5225,6615,8876,7948,0298,64610,1698,62710,04610,0468,62510,1759,7119,8488,0776,0086,0547,49814,62421,20424,2831,8701,8201,9772,0481,8641,6011,6961,6461,4661,7562,0682,3472,3162,2812,5162,1312,3302,3311,8262,7322,7323,5757,3818,7376,5627,5425,7716,3026,8959,3029,7408,1008,10010,50011,70012,70013,30015,00016,30018,30020,00021,40022,50023,10024,70023,40015,40011,5009,7009,4007,2006,0006,6007,4007,2007,7008,7007,9006,0005,7004,4004,3004,5004,5004,3004,2004,2004,3004,2004,2004,2004,2004,2000002,1000001,2000001,5000003,300
   > Total Current Assets 
3,000
0
0
0
1,100
0
0
0
700
0
0
0
1,900
0
0
0
4,000
4,000
4,100
4,000
4,000
4,100
4,000
4,100
4,200
4,300
4,300
4,100
4,200
5,500
5,800
7,600
8,400
7,400
6,800
7,100
6,300
5,700
6,900
8,800
9,000
10,300
14,000
21,500
22,600
21,000
20,600
19,600
18,200
16,700
14,800
13,700
9,000
8,600
7,700
7,200
7,500
7,600
9,310
8,952
3,655
3,121
2,641
4,549
3,580
5,753
4,445
3,480
2,654
2,654
1,768
2,280
2,285
2,089
2,476
2,241
2,272
2,305
2,029
1,720
1,434
1,611
1,566
1,364
1,623
1,597
1,524
1,368
1,416
1,553
1,622
2,316
2,257
2,831
2,386
2,179
2,396
2,122
1,974
1,528
1,235
1,235
1,785
3,644
3,120
2,610
1,788
1,145
922
1,780
1,326
1,029
1,234
3,367
3,630
6,435
6,322
10,571
8,523
7,754
6,896
6,187
4,801
4,006
3,400
2,069
5,192
6,446
7,014
7,013,940
5,775
5,721
5,720
5,538
6,236
7,494
6,628
6,093
5,869
5,657
9,264
9,369
14,564
38,472
37,052
36,003
34,994
32,563
32,340
30,200
28,105
27,410
26,400
25,356
25,219
25,21925,35626,40027,41028,10530,20032,34032,56334,99436,00337,05238,47214,5649,3699,2645,6575,8696,0936,6287,4946,2365,5385,7205,7215,7757,013,9407,0146,4465,1922,0693,4004,0064,8016,1876,8967,7548,52310,5716,3226,4353,6303,3671,2341,0291,3261,7809221,1451,7882,6103,1203,6441,7851,2351,2351,5281,9742,1222,3962,1792,3862,8312,2572,3161,6221,5531,4161,3681,5241,5971,6231,3641,5661,6111,4341,7202,0292,3052,2722,2412,4762,0892,2852,2801,7682,6542,6543,4804,4455,7533,5804,5492,6413,1213,6558,9529,3107,6007,5007,2007,7008,6009,00013,70014,80016,70018,20019,60020,60021,00022,60021,50014,00010,3009,0008,8006,9005,7006,3007,1006,8007,4008,4007,6005,8005,5004,2004,1004,3004,3004,2004,1004,0004,1004,0004,0004,1004,0004,0000001,9000007000001,1000003,000
       Cash And Cash Equivalents 
2,800
0
0
0
1,000
0
0
0
700
0
0
0
1,700
0
0
0
2,200
2,500
1,700
2,200
2,100
2,100
3,000
2,100
4,100
4,300
4,300
4,100
4,100
5,400
5,800
7,600
8,300
7,400
6,800
7,000
6,200
5,700
6,900
8,700
8,900
10,200
13,900
21,400
22,200
19,500
18,500
15,800
12,300
11,200
8,000
6,100
5,400
4,400
3,700
2,300
1,600
2,100
3,589
2,621
1,134
703
158
2,016
1,317
3,455
2,142
1,302
855
855
408
1,057
1,024
868
1,243
1,040
1,003
1,012
641
582
507
809
732
611
1,282
828
766
653
669
794
764
458
479
1,716
1,291
321
1,451
1,197
1,075
1,409
1,094
1,094
347
551
774
463
131
102
340
1,713
1,274
982
898
776
618
3,652
3,361
7,810
6,080
5,161
4,369
3,981
2,612
2,049
2,488
1,400
2,877
1,834
3,339
3,339,374
2,847
4,172
2,591
3,056
4,153
3,822
4,397
3,492
2,822
2,888
5,928
6,417
11,983
27,703
27,222
29,128
29,781
27,732
24,254
12,360
9,790
5,620
3,198
915
998
9989153,1985,6209,79012,36024,25427,73229,78129,12827,22227,70311,9836,4175,9282,8882,8223,4924,3973,8224,1533,0562,5914,1722,8473,339,3743,3391,8342,8771,4002,4882,0492,6123,9814,3695,1616,0807,8103,3613,6526187768989821,2741,7133401021314637745513471,0941,0941,4091,0751,1971,4513211,2911,7164794587647946696537668281,2826117328095075826411,0121,0031,0401,2438681,0241,0574088558551,3022,1423,4551,3172,0161587031,1342,6213,5892,1001,6002,3003,7004,4005,4006,1008,00011,20012,30015,80018,50019,50022,20021,40013,90010,2008,9008,7006,9005,7006,2007,0006,8007,4008,3007,6005,8005,4004,1004,1004,3004,3004,1002,1003,0002,1002,1002,2001,7002,5002,2000001,7000007000001,0000002,800
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
500
0
97
97
97
97
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
396
398
401
403
398
398
38
425
425
400
400
441
441
1,440
1,442
750
750
1,650
750
750
750
0
0
0
1,349
2,999
2,249
2,050
1,550
950
500
500
0
0
0
2,450
2,050
2,550
2,500
2,650
2,400
2,400
2,400
2,150
2,150
1,900
750
600
2,250
4,251
3,500
3,500,000
2,650
1,250
2,750
2,000
1,750
2,750
2,100
2,350
2,870
2,620
3,140
2,640
2,000
10,399
9,400
6,600
4,749
4,499
7,410
17,327
17,912
21,356
22,336
22,929
22,800
22,80022,92922,33621,35617,91217,3277,4104,4994,7496,6009,40010,3992,0002,6403,1402,6202,8702,3502,1002,7501,7502,0002,7501,2502,6503,500,0003,5004,2512,2506007501,9002,1502,1502,4002,4002,4002,6502,5002,5502,0502,4500005005009501,5502,0502,2492,9991,3490007507507501,6507507501,4421,4404414414004004254253839839840340139839600000000000000009797979705005000000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
478
595
561
708
694
536
562
507
525
401
401
215
177
169
140
145
150
148
288
99
173
62
30
68
37
10
69
60
60
120
60
191
207
103
112
106
12
1
1
8
5
0
0
0
0
0
0
0
0
0
0
0
0
175
175
828
133
400
45
0
0
0
0
0
0
0
0
0
221
0
0
0
0
0
0
0
797
1
67
22
32
6
2
0
0
0
0
0
0
0
46
147
256
334
270
391
391270334256147460000000263222671797000000022100000000045400133828175175000000000000581112106112103207191601206060691037683062173992881481501451401691772154014015255075625366947085615954780000000000000000000000000000000000000000001,8000000000000000000
       Inventory 
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,800
0
3,000
2,800
3,600
4,500
4,400
4,360
4,868
1,769
1,834
1,761
1,620
1,589
1,497
1,601
1,517
1,296
1,296
1,032
1,028
1,045
1,036
1,064
1,033
999
977
877
555
385
330
308
281
261
243
231
214
192
225
196
185
178
177
176
138
133
110
93
59
52
52
32
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-46
0
0
0
0
0
00000-460000000000000000000000000000000000000000000003332525259931101331381761771781851962251922142312432612813083303855558779779991,0331,0641,0361,0451,0281,0321,2961,2961,5171,6011,4971,5891,6201,7611,8341,7694,8684,3604,4004,5003,6002,8003,00001,80000000000000000000000000000000000000000000000000000100
       Other Current Assets 
100
0
0
0
100
0
0
0
0
0
0
0
200
0
0
0
0
1,500
2,400
1,800
1,900
2,000
1,000
2,000
100
0
0
0
100
100
0
0
100
0
0
100
100
0
0
100
100
100
100
100
400
1,500
2,100
3,800
5,900
5,500
6,800
5,800
3,600
1,200
1,200
800
900
1,100
1,264
888
60
23
14
219
137
239
194
137
103
103
113
17
48
45
23
18
122
27
17
12
401
38
60
36
32
32
42
41
35
33
30
26
54
77
63
58
62
65
48
56
89
89
57
61
97
97
107
93
82
67
52
47
161
141
134
101
61
66
43
194
127
56
39
56
162
69
65
140
175
0
278
298
378
482
334
124
130
185
154
116
190
309
581
369
430
276
464
332
676
513
256
178
532
1,242
1,030
1,0301,2425321782565136763324642764303695813091901161541851301243344823782982780175140656916256395612719443666110113414116147526782931079797615789895648656258637754263033354142323236603840112172712218234548171131031031371942391372191423608881,2641,1009008001,2001,2003,6005,8006,8005,5005,9003,8002,1001,5004001001001001001000010010000100001001000001002,0001,0002,0001,9001,8002,4001,50000002000000000100000100
   > Long-term Assets 
300
0
0
0
400
0
0
0
500
0
0
0
200
0
0
0
200
200
100
200
200
200
200
100
100
200
200
200
200
200
200
300
300
300
400
300
300
300
300
600
700
1,200
1,400
1,900
2,100
2,100
1,900
1,800
1,800
1,600
1,500
1,300
4,300
4,100
4,000
3,300
600
500
430
350
3,239
3,181
3,130
2,993
2,983
2,984
2,936
96
77
77
58
52
45
41
40
40
44
42
39
35
32
36
130
238
241
450
453
452
455
22,729
19,582
12,308
5,241
3,223
3,621
5,898
7,452
7,589
8,202
7,096
0
8,811
6,842
6,524
5,525
5,420
5,006
4,742
4,739
5,742
6,028
4,278
4,206
6,960
6,870
6,964
2,734
2,699
2,610
2,525
2,440
2,461
2,404
2,316
2,228
2,150
2,058
1,969
1,798
0
1,715
1,640
1,574
910
234
272
215
201
295
268
98
84
40
26
10
254
244
234
223
212
201
189
178
166
153
15316617818920121222323424425410264084982682952012152722349101,5741,6401,71501,7981,9692,0582,1502,2282,3162,4042,4612,4402,5252,6102,6992,7346,9646,8706,9604,2064,2786,0285,7424,7394,7425,0065,4205,5256,5246,8428,81107,0968,2027,5897,4525,8983,6213,2235,24112,30819,58222,7294554524534502412381303632353942444040414552587777962,9362,9842,9832,9933,1303,1813,2393504305006003,3004,0004,1004,3001,3001,5001,6001,8001,8001,9002,1002,1001,9001,4001,200700600300300300300400300300300200200200200200200100100200200200200100200200000200000500000400000300
       Property Plant Equipment 
300
0
0
0
300
0
0
0
300
0
0
0
200
0
0
0
100
100
100
100
100
100
100
100
-500
100
-500
100
100
100
100
100
200
200
200
200
200
200
200
200
200
200
500
500
800
900
900
900
900
900
900
800
800
700
700
600
500
500
403
325
270
212
162
129
119
121
103
84
72
72
53
46
39
36
35
34
38
37
33
30
27
31
28
26
23
22
25
24
27
31
33
31
30
27
24
24
21
19
17
15
15
15
19
18
16
15
14
12
10
11
8
9
8
8
8
10
12
59
51
47
43
146
171
163
157
160
149
141
53
52,701
51
57
72
73
67
230
215
201
295
268
68
54
40
26
10
254
244
234
223
212
201
189
178
166
153
1531661781892012122232342442541026405468268295201215230677372575152,701531411491601571631711464347515912108889811101214151618191515151719212424273031333127242522232628312730333738343536394653727284103121119129162212270325403500500600700700800800900900900900900900800500500200200200200200200200200200200100100100100100-500100-500100100100100100100100100000200000300000300000300
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,506
5,510
5,405
4,992
4,730
4,728
5,731
6,021
4,269
4,197
3,986
3,977
4,151
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000004,1513,9773,9864,1974,2696,0215,7314,7284,7304,9925,4055,5106,5060000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,966
2,884
2,803
2,722
2,640
2,559
2,478
2,396
2,315
2,234
2,152
2,071
1,990
1,908
1,827
1,746
0
1,664
1,583
1,502
838
168
42
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000421688381,5021,5831,66401,7461,8271,9081,9902,0712,1522,2342,3152,3962,4782,5592,6402,7222,8032,8842,96600000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27
26
25
2,970
2,969
2,968
2,864
2,863
2,863
2,833
11
6
6
5
5
6
6
6
6
6
5
6
5
5
5
102
211
218
428
428
428
427
22,699
19,549
12,277
5,211
3,196
3,598
5,874
7,431
7,570
8,184
7,082
8,796
7,155
6,823
6,507
5,510
5,405
4,992
4,730
4,729
5,731
6,021
4,270
4,197
6,952
6,862
6,954
2,721
2,640
2,559
2,478
2,397
2,315
2,234
2,152
2,071
1,990
1,908
1,827
1,746
0
1,665
1,583
1,503
838
0
0
0
0
0
0
30
84
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000084300000008381,5031,5831,66501,7461,8271,9081,9902,0712,1522,2342,3152,3972,4782,5592,6402,7216,9546,8626,9524,1974,2706,0215,7314,7294,7304,9925,4055,5106,5076,8237,1558,7967,0828,1847,5707,4315,8743,5983,1965,21112,27719,54922,69942742842842821821110255565666665566112,8332,8632,8632,8642,9682,9692,970252627000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
200
0
0
0
200
0
0
0
100
0
0
0
100
0
0
0
100
100
100
100
100
100
100
100
100
200
200
200
300
300
400
300
500
600
400
300
200
300
300
200
300
500
500
800
1,900
1,500
1,300
1,500
1,200
1,300
1,100
1,400
1,400
1,400
1,300
1,600
1,800
2,000
2,075
2,335
1,337
1,269
1,147
3,202
2,396
4,114
1,535
394
414
414
421
390
342
383
408
360
443
422
293
270
348
472
372
292
582
367
328
320
679
5,587
5,483
6,594
5,768
5,680
5,456
5,212
5,396
5,391
5,389
5,492
5,450
5,450
5,552
7,927
7,588
7,291
7,133
6,780
6,855
8,846
8,800
8,545
8,760
15,997
15,346
13,250
5,046
5,013
4,143
4,282
4,282
5,056
4,646
4,603
4,641
8,037
3,660
2,927
889
8,812,416
1,087
1,340
1,129
1,265
1,327
1,596
1,444
1,481
1,166
1,103
1,224
1,189
1,525
1,443
1,208
1,491
1,996
1,391
1,656
2,212
1,394
1,686
1,993
2,151
1,768
1,7682,1511,9931,6861,3942,2121,6561,3911,9961,4911,2081,4431,5251,1891,2241,1031,1661,4811,4441,5961,3271,2651,1291,3401,0878,812,4168892,9273,6608,0374,6414,6034,6465,0564,2824,2824,1435,0135,04613,25015,34615,9978,7608,5458,8008,8466,8556,7807,1337,2917,5887,9275,5525,4505,4505,4925,3895,3915,3965,2125,4565,6805,7686,5945,4835,5876793203283675822923724723482702934224433604083833423904214144143941,5354,1142,3963,2021,1471,2691,3372,3352,0752,0001,8001,6001,3001,4001,4001,4001,1001,3001,2001,5001,3001,5001,900800500500300200300300200300400600500300400300300200200200100100100100100100100100100000100000100000200000200
   > Total Current Liabilities 
200
0
0
0
200
0
0
0
100
0
0
0
100
0
0
0
100
100
100
100
100
100
200
100
200
200
200
200
300
200
400
300
400
600
400
300
200
300
300
200
200
400
600
700
2,000
1,500
1,400
1,500
1,200
1,300
1,100
1,400
1,500
1,400
1,300
1,600
1,800
2,000
2,075
2,335
1,337
1,269
1,147
3,202
2,396
4,114
1,535
394
414
414
421
390
342
383
408
360
443
422
293
270
348
472
372
292
582
367
328
320
679
587
483
1,594
768
680
456
212
396
391
389
492
450
450
552
2,927
2,105
2,055
2,133
1,780
1,822
3,439
3,301
3,095
3,212
11,548
10,682
8,357
1,810
1,667
689
712
594
1,244
707
532
469
3,724
3,660
2,927
889
889,493
1,087
1,340
1,129
1,265
1,327
1,596
1,444
1,481
1,126
1,077
1,213
1,189
1,525
1,443
1,208
1,271
1,787
1,189
1,469
2,037
1,232
1,537
1,857
2,028
1,660
1,6602,0281,8571,5371,2322,0371,4691,1891,7871,2711,2081,4431,5251,1891,2131,0771,1261,4811,4441,5961,3271,2651,1291,3401,087889,4938892,9273,6603,7244695327071,2445947126891,6671,8108,35710,68211,5483,2123,0953,3013,4391,8221,7802,1332,0552,1052,9275524504504923893913962124566807681,5944835876793203283675822923724723482702934224433604083833423904214144143941,5354,1142,3963,2021,1471,2691,3372,3352,0752,0001,8001,6001,3001,4001,5001,4001,1001,3001,2001,5001,4001,5002,000700600400200200300300200300400600400300400200300200200200200100200100100100100100100000100000100000200000200
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
582
610
691
957
5,668
5,000
5,000
0
0
0
0
0
0
0
0
0
3,000
3,000
2,000
0
0
0
0
0
0
0
0
0
0
53
56
58
55
41
26
11
39
41
39
44
46
47
49
51
52
54
545251494746443941391126415558565300000000002,0003,0003,0000000000005,0005,0005,6689576916105820000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
100
100
100
100
100
200
200
200
300
200
400
300
400
600
400
300
200
200
300
200
200
400
500
700
2,000
1,500
1,400
1,500
1,200
1,300
1,100
1,400
1,400
1,200
1,200
1,300
1,500
1,700
1,949
2,167
1,036
1,045
940
815
816
548
410
341
379
379
380
353
317
334
374
323
403
398
252
231
271
404
313
253
533
318
199
244
347
403
424
308
385
470
294
104
326
315
304
390
356
356
456
278
375
449
559
463
305
489
534
516
527
492
458
529
540
578
389
425
375
560
418
445
469
541
448
445
480
0
1,087
452
419
582
613
718
568
586
367
171
339
232
512
438
208
136
504
93
227
265
110
195
94
206
364
36420694195110265227935041362084385122323391713675865687186135824194521,08704804454485414694454185603754253895785405294584925275165344893054635594493752784563563563903043153261042944703853084244033472441993185332533134042712312523984033233743343173533803793793414105488168159401,0451,0362,1671,9491,7001,5001,3001,2001,2001,4001,4001,1001,3001,2001,5001,4001,5002,00070050040020020030020020030040060040030040020030020020020010010010010010010010010000000000000000000
       Other Current Liabilities 
200
0
0
0
200
0
0
0
100
0
0
0
100
0
0
0
100
0
0
0
0
0
100
0
100
0
0
0
0
0
0
0
0
0
0
0
0
100
0
0
0
0
100
0
0
0
0
0
0
0
0
0
100
200
100
300
300
300
126
168
301
224
206
220
38
57
41
53
35
35
42
37
25
49
34
37
40
24
41
39
77
68
59
39
49
49
129
76
332
184
59
56
69
210
161
108
70
76
86
103
94
94
96
75
86
162
140
130
331
1,180
970
700
540
4,201
4,037
1,900
1,269
1,090
300
287
219
684
289
87
96
183
212
482
409
0
1,087
888
710
683
714
878
876
895
705
850
816
901
973
979
990
1,095
1,242
1,057
1,198
1,726
1,075
1,293
1,712
1,770
1,242
1,2421,7701,7121,2931,0751,7261,1981,0571,2421,0959909799739018168507058958768787146837108881,087040948221218396872896842192873001,0901,2691,9004,0374,2015407009701,180331130140162867596949410386767010816121069565918433276129494939596877394124403734492537423535534157382202062243011681263003003001002001000000000001000000100000000000000100010000000100000100000100000200000200
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
100
100
100
100
-100
100
-100
200
200
200
300
100
400
300
100
600
400
300
200
200
300
200
100
100
-100
100
-100
1,500
-100
1,500
1,200
1,300
1,100
1,400
-100
1,200
1,200
1,300
1,500
1,700
1,949
2,167
1,036
1,045
940
2,982
2,358
4,057
1,494
341
0
379
380
353
317
334
374
323
403
398
252
231
271
404
313
253
533
318
199
244
347
5,000
5,000
5,000
5,000
5,000
5,000
5,000
5,000
5,000
5,000
5,000
0
5,000
5,000
5,000
5,483
5,236
5,000
5,000
5,032
5,408
5,499
5,451
5,549
4,449
4,664
4,893
3,236
3,345
3,454
3,570
3,688
3,812
3,939
4,071
4,172
4,313
3,448
2,445
480
0
409,169
452
419
582
613
718
568
586
41
26
11
288
553
464
218
220
209
202
187
175
162
149
136
123
108
108123136149162175187202209220218464553288112641586568718613582419452409,16904802,4453,4484,3134,1724,0713,9393,8123,6883,5703,4543,3453,2364,8934,6644,4495,5495,4515,4995,4085,0325,0005,0005,2365,4835,0005,0005,00005,0005,0005,0005,0005,0005,0005,0005,0005,0005,0005,00034724419931853325331340427123125239840332337433431735338037903411,4944,0572,3582,9829401,0451,0362,1671,9491,7001,5001,3001,2001,200-1001,4001,1001,3001,2001,500-1001,500-100100-100100100200300200200300400600100300400100300200200200-100100-10010010010010010000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
408
454
451
549
1,512
1,627
1,756
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000001,7561,6271,51254945145440832000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
483
236
0
0
0
0
46
0
0
2,937
3,037
3,136
3,236
3,346
3,454
3,569
3,688
3,812
3,939
4,071
4,172
4,313
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000004,3134,1724,0713,9393,8123,6883,5693,4543,3463,2363,1363,0372,9370046000023648300000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
483
236
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000023648300000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
3,100
0
0
0
1,300
0
0
0
1,100
0
0
0
2,000
0
0
0
4,100
4,100
4,100
4,100
4,100
4,200
4,100
4,100
4,200
4,300
4,300
4,100
4,100
5,400
5,600
7,600
8,200
7,100
6,800
7,100
6,400
5,700
6,900
9,200
9,400
11,000
14,900
22,600
22,800
21,600
21,200
19,900
18,800
17,000
15,200
13,600
11,900
11,300
10,400
8,900
6,300
6,100
7,664
6,967
5,558
5,033
4,624
4,340
4,167
4,623
5,846
3,182
2,317
2,317
1,405
1,941
1,988
1,747
2,108
1,920
1,873
1,925
1,775
1,486
1,118
1,174
1,325
1,309
1,282
1,680
1,649
1,500
1,191
18,696
15,720
8,030
1,730
374
552
2,865
4,452
4,320
4,786
3,132
4,596
4,596
3,075
2,241
1,058
738
-339
-893
-1,194
-1,324
-1,446
-3,238
-3,321
-5,669
-4,846
150
4,010
8,258
6,990
5,998
5,054
3,591
2,560
1,718
987
-3,819
3,589
5,488
7,923
0
6,436
6,066
6,326
5,435
5,479
6,543
5,799
5,235
5,445
5,287
8,618
8,761
13,600
37,614
36,467
35,437
33,963
32,171
31,701
29,047
27,791
26,811
25,520
24,337
24,605
24,60524,33725,52026,81127,79129,04731,70132,17133,96335,43736,46737,61413,6008,7618,6185,2875,4455,2355,7996,5435,4795,4356,3266,0666,43607,9235,4883,589-3,8199871,7182,5603,5915,0545,9986,9908,2584,010150-4,846-5,669-3,321-3,238-1,446-1,324-1,194-893-3397381,0582,2413,0754,5964,5963,1324,7864,3204,4522,8655523741,7308,03015,72018,6961,1911,5001,6491,6801,2821,3091,3251,1741,1181,4861,7751,9251,8731,9202,1081,7471,9881,9411,4052,3172,3173,1825,8464,6234,1674,3404,6245,0335,5586,9677,6646,1006,3008,90010,40011,30011,90013,60015,20017,00018,80019,90021,20021,60022,80022,60014,90011,0009,4009,2006,9005,7006,4007,1006,8007,1008,2007,6005,6005,4004,1004,1004,3004,3004,2004,1004,1004,2004,1004,1004,1004,1004,1000002,0000001,1000001,3000003,100
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
600
600
600
629
631
631
638
645
656
665
673
680
688
703
703
745
788
802
813
836
846
855
869
885
905
920
938
952
968
993
1,019
1,035
1,049
1,069
1,286
1,300
1,311
1,325
1,354
1,390
1,418
1,446
1,460
1,484
1,507
1,537
1,537
1,686
1,722
1,761
1,805
1,815
1,842
1,850
1,851
1,999
2,062
2,093
2,105
2,194
2,368
2,197
2,197
2,189
87
87
87
87
87
88
88
117
151
166
0
166
169
187
189
195
200
202
203
208
215
237
242
262
314
299
301
301
302
307
309
309
310
310
311
318
3183113103103093093073023013012993142622422372152082032022001951891871691660166151117888887878787872,1892,1972,1972,3682,1942,1052,0932,0621,9991,8511,8501,8421,8151,8051,7611,7221,6861,5371,5371,5071,4841,4601,4461,4181,3901,3541,3251,3111,3001,2861,0691,0491,0351,0199939689529389209058858698558468368138027887457037036886806736656566456386316316296006006000000000000000000000000000000000000000000000000000000000
   Retained Earnings -231,451-228,196-225,506-222,995-220,707-218,385-214,909-212,163-208,619-204,790-200,777-196,443-194,044-191,836-189,612-187,050-184,410-181,817-179,730-177,590-175,052-170,170-164,868-159,391-158,0120-156,174-154,388-152,594-152,754-151,165-150,118-149,014-147,742-146,149-144,856-143,254-141,018-144,770-141,616-142,027-138,778-135,163-132,237-129,655-127,178-125,083-123,223-122,594-121,717-120,831-118,039-116,266-113,452-113,452-112,326-111,055-109,784-108,277-95,693-94,507-93,163-91,788-91,223-90,493-88,652-85,967-84,769-83,714-82,282-80,509-78,707-76,560-74,147-72,908-71,762-70,643-69,463-68,456-67,634-66,600-65,905-65,096-64,407-63,756-61,981-61,981-60,767-57,738-58,636-58,696-57,989-57,042-56,254-55,124-53,715-52,741-51,500-50,200-46,600-44,700-43,100-41,700-40,000-38,300-36,500-34,500-33,200-31,700-30,100-28,800-26,800-25,300-24,300-23,300-22,400-21,700-21,000-20,300-19,700-18,800-18,000-16,900-15,500-15,500-14,100-14,100-12,300-12,300-12,300-12,300-11,000-11,000-11,000-11,000-10,200-10,200-10,200-9,900000-8,800000-7,500000-6,100000-4,300
   Accumulated Other Comprehensive Income 
-100
0
0
0
-100
0
0
0
-200
0
0
0
-300
0
0
0
-400
-500
-500
-500
-500
-500
-500
-500
-500
-500
-500
-500
-500
-500
-600
-600
-600
-600
-600
-600
-600
-600
-700
-700
-700
-700
-700
-800
-800
-900
-900
-1,000
-1,100
-1,100
-1,200
-1,300
-1,400
-1,400
-1,500
-1,600
-1,600
-1,700
-1,760
-1,776
-1,838
-1,838
-1,838
-1,838
-2,004
-2,004
-2,004
-2,004
-2,051
-2,051
-2,051
-2,051
-2,084
-2,084
-2,084
-2,084
-2,101
-2,101
-2,101
-2,101
-2,116
-2,116
-2,116
-2,116
-2,131
-2,131
-2,131
-2,131
-2,141
1,071
-2,079
-10,345
-17,155
-13,390
-12,986
-10,702
-2,162
158
776
-308
1,000
1,412
-473
-789
-2,178
-105
-518
-779
-654
349
639
-1,113
0
-211
-220
-46
-350
-2
-6
-10
-14
-17
-27
-39
-102
-57
-68
-79
-36
0
-40
-43
-48
-54
-60
-72
-87
-95
-110
-124
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000-124-110-95-87-72-60-54-48-43-400-36-79-68-57-102-39-27-17-14-10-6-2-350-46-220-2110-1,113639349-654-779-518-105-2,178-789-4731,4121,000-308776158-2,162-10,702-12,986-13,390-17,155-10,345-2,0791,071-2,141-2,131-2,131-2,131-2,131-2,116-2,116-2,116-2,116-2,101-2,101-2,101-2,101-2,084-2,084-2,084-2,084-2,051-2,051-2,051-2,051-2,004-2,004-2,004-2,004-1,838-1,838-1,838-1,838-1,776-1,760-1,700-1,600-1,600-1,500-1,400-1,400-1,300-1,200-1,100-1,100-1,000-900-900-800-800-700-700-700-700-700-600-600-600-600-600-600-600-600-500-500-500-500-500-500-500-500-500-500-500-500-500-400000-300000-200000-100000-100
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
124,348
125,127
125,755
125,958
126,267
127,693
128,655
130,571
133,050
134,750
136,214
140,207
144,444
146,232
146,728
147,705
150,753
151,101
151,232
151,472
151,734
152,051
148,848
156,066
159,725
163,931
0
164,282
165,289
171,007
175,416
180,337
183,933
185,327
186,849
189,646
192,122
197,993
200,354
207,382
233,742
236,944
0
0
244,032
246,303
247,123
248,189
249,496
250,716
0
0
00250,716249,496248,189247,123246,303244,03200236,944233,742207,382200,354197,993192,122189,646186,849185,327183,933180,337175,416171,007165,289164,2820163,931159,725156,066148,848152,051151,734151,472151,232151,101150,753147,705146,728146,232144,444140,207136,214134,750133,050130,571128,655127,693126,267125,958125,755125,127124,3480000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
7,500
0
0
0
7,500
0
0
0
8,800
0
0
0
11,100
0
0
0
14,400
14,800
14,800
14,800
15,600
15,700
15,600
15,600
17,000
17,100
17,100
16,900
18,700
20,000
21,700
23,700
25,700
25,700
26,200
27,400
27,300
27,300
29,300
32,300
33,400
36,000
40,900
50,200
52,400
52,600
53,800
54,100
54,400
54,600
54,700
54,900
55,000
55,800
56,600
56,500
57,500
58,700
61,536
61,827
61,889
62,487
62,860
63,511
64,202
64,590
64,908
65,265
65,647
65,647
66,467
67,611
68,366
68,923
69,955
70,793
71,575
72,620
73,633
74,444
75,222
76,498
79,048
81,165
82,929
85,075
86,459
87,351
88,230
104,991
106,993
108,286
109,349
105,573
106,655
107,842
111,284
113,818
114,906
115,617
0
117,904
119,795
121,052
120,127
122,559
120,958
121,267
123,234
124,979
127,017
131,288
133,071
136,884
140,053
139,444
146,582
146,730
147,711
150,763
151,115
151,249
151,500
151,773
152,153
148,848
156,066
159,725
163,931
0
164,282
165,289
171,007
175,416
180,337
183,933
185,327
186,849
189,646
192,122
197,993
200,354
207,382
233,742
236,944
239,927
242,281
244,032
246,303
247,123
248,189
249,496
250,716
252,222
255,738
255,738252,222250,716249,496248,189247,123246,303244,032242,281239,927236,944233,742207,382200,354197,993192,122189,646186,849185,327183,933180,337175,416171,007165,289164,2820163,931159,725156,066148,848152,153151,773151,500151,249151,115150,763147,711146,730146,582139,444140,053136,884133,071131,288127,017124,979123,234121,267120,958122,559120,127121,052119,795117,9040115,617114,906113,818111,284107,842106,655105,573109,349108,286106,993104,99188,23087,35186,45985,07582,92981,16579,04876,49875,22274,44473,63372,62071,57570,79369,95568,92368,36667,61166,46765,64765,64765,26564,90864,59064,20263,51162,86062,48761,88961,82761,53658,70057,50056,50056,60055,80055,00054,90054,70054,60054,40054,10053,80052,60052,40050,20040,90036,00033,40032,30029,30027,30027,30027,40026,20025,70025,70023,70021,70020,00018,70016,90017,10017,10017,00015,60015,60015,70015,60014,80014,80014,80014,40000011,1000008,8000007,5000007,500



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-10-31)

Gross Profit (+$)
totalRevenue210
Cost of Revenue-161
Gross Profit4949
 
Operating Income (+$)
Gross Profit49
Operating Expense-11,060
Operating Income-11,011-11,011
 
Operating Expense (+$)
Research Development4,769
Selling General Administrative6,291
Selling And Marketing Expenses0
Operating Expense11,06011,060
 
Net Interest Income (+$)
Interest Income1,081
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,081
 
Pretax Income (+$)
Operating Income-11,011
Net Interest Income1,081
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-9,930-12,092
EBIT - interestExpense = -11,011
-9,930
-9,811
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-11,011-9,930
Earnings Before Interest and Taxes (EBITDA)-10,965
 
After tax Income (+$)
Income Before Tax-9,930
Tax Provision-0
Net Income From Continuing Ops-9,930-9,930
Net Income-9,811
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses11,221
Total Other Income/Expenses Net1,081-1,081
 

Technical Analysis of Anixa
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Anixa. The general trend of Anixa is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Anixa's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Anixa Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 3.01 < 3.4241 < 3.8.

The bearish price targets are: 2.77 > 2.75.

Tweet this
Anixa Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Anixa Biosciences Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Anixa Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Anixa Biosciences Inc. The current macd is -0.10323302.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Anixa price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Anixa. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Anixa price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Anixa Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartAnixa Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Anixa Biosciences Inc. The current adx is 11.28.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Anixa shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Anixa Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Anixa Biosciences Inc. The current sar is 3.3999.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Anixa Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Anixa Biosciences Inc. The current rsi is 40.17. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Anixa Biosciences Inc Daily Relative Strength Index (RSI) ChartAnixa Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Anixa Biosciences Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Anixa price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Anixa Biosciences Inc Daily Stochastic Oscillator ChartAnixa Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Anixa Biosciences Inc. The current cci is -116.26915917.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Anixa Biosciences Inc Daily Commodity Channel Index (CCI) ChartAnixa Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Anixa Biosciences Inc. The current cmo is -22.96306362.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Anixa Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartAnixa Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Anixa Biosciences Inc. The current willr is -91.73724437.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Anixa Biosciences Inc Daily Williams %R ChartAnixa Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Anixa Biosciences Inc.

Anixa Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Anixa Biosciences Inc. The current atr is 0.20901711.

Anixa Biosciences Inc Daily Average True Range (ATR) ChartAnixa Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Anixa Biosciences Inc. The current obv is 2,104,333.

Anixa Biosciences Inc Daily On-Balance Volume (OBV) ChartAnixa Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Anixa Biosciences Inc. The current mfi is 50.26.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Anixa Biosciences Inc Daily Money Flow Index (MFI) ChartAnixa Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Anixa Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Anixa Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Anixa Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.170
Ma 20Greater thanMa 503.157
Ma 50Greater thanMa 1003.383
Ma 100Greater thanMa 2003.800
OpenGreater thanClose3.250
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Anixa with someone you think should read this too:
  • Are you bullish or bearish on Anixa? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Anixa? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Anixa Biosciences Inc

I send you an email if I find something interesting about Anixa Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Anixa Biosciences Inc.

Receive notifications about Anixa Biosciences Inc in your mailbox!